UNSPSC 51102856: Hydrocortisone/neomycin/polymyxin b

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102856 Hydrocortisone/neomycin/polymyxin b is a Commodity code that in recent state and local procurement activity spans pharmaceutical products and public health supplies, though the opportunities posted under this code do not consistently align with the nominal product scope. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets over a three-year term; Seminole County, Florida issued an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually. State and local health departments and county public health agencies are the primary issuing bodies soliciting under or adjacent to this code. Illinois Department of Public Health used cooperative-purchasing vehicles (piggyback arrangements through consortium agreements) to execute pharmaceutical procurements, while Seminole County managed the naloxone procurement directly with a two-year initial term and one-year renewal option. Most recent activity centers on Illinois and Florida, with secondary exposure likely across other states through cooperative purchasing channels and health department networks.

The Illinois opportunity used an Invitation for Bid process and was awarded as a completed contract in August 2026 with no set-aside or preference designations; the Seminole County naloxone IFB posted June 30, 2026, with a response deadline of July 26, 2026 (now closed), and required quarterly deliveries to the Seminole County Community Health Building in Sanford. Both procurements emphasize volume ordering with multi-year or renewal terms typical of state and local health supply chains. The code shows limited recent activity directly matching its nominal scope; most opportunities in the block represent broader pharmaceutical and public-health-supply procurement rather than the specific hydrocortisone/neomycin/polymyxin b antibiotic combination named in the code definition.